Latest Headlines

  1. Alzheimer’s Drug Discovery Foundation (ADDF) And Target ALS Announce Partnership To Accelerate Biomarker Discovery And Development 12/21/2021

    The Alzheimer’s Drug Discovery Foundation (ADDF) and Target ALS announced today a new partnership to identify and develop biomarkers for neurodegenerative diseases, including Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD).

  2. Acadia Pharmaceuticals Announces Plan For A Resubmission Of Its Supplemental New Drug Application To U.S. FDA For NUPLAZID (pimavanserin) 12/20/2021

    Acadia Pharmaceuticals Inc. announced today that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (ADP). Resubmission of the sNDA to the U.S. Food and Drug Administration (FDA) is planned for the first quarter of 2022.

  3. Poseida Therapeutics Announces FDA Clearance Of Investigational New Drug Application For P-MUC1C-ALLO1, A Fully Allogeneic CAR-T Targeting Multiple Solid Tumors 12/20/2021

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-MUC1C-ALLO1, the Company's allogeneic CAR-T product candidate targeting multiple solid tumor indications.

  4. Basilea Announces FDA Approval Of Investigational New Drug Application For Novel Oncology Drug Candidate BAL0891 12/17/2021

    Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the novel kinase inhibitor BAL0891, a potential first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division leading to tumor cell death.

  5. Aqemia And Servier Announce AI And Quantum Physics-Drive Drug Discovery Collaboration In Immuno-Oncology 12/17/2021

    Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics, and Servier, a global pharmaceutical group, announced today that they have entered into a collaboration agreement that will use Aqemia's technology to accelerate the discovery of small molecule therapeutic drug candidates on an undisclosed target in immuno-oncology. 

  6. Iktos And The University Of Dundee, Drug Discovery Unit (DDU) Announce A Collaboration To Use AI For Drug Design And Retrosyntheis 12/17/2021

    Iktos, a company specialized in Artificial Intelligence for new drug design, and The Drug Discovery Unit (DDU), School of Life Sciences, The University of Dundee, focused on the discovery of therapeutics for neglected diseases and the translation of novel biology through small molecule drug discovery, today announced entering a collaboration to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of DDU’s drug discovery programs.

  7. Eppendorf Research Plus Is The First Pipette To Receive My Green Lab ACT Label 12/17/2021

    The Eppendorf Research® plus single-channel pipette line-up with variable volume has been certified with an “ACT®” Environmental Impact Factor Label by the “My Green Lab®” non-profit organization.

  8. Sosei Heptares Enters Antibody Discovery Agreement With Twist Bioscience To Discover And Develop Novel Therapeutic Antibodies Against GPCR Targets 12/16/2021

    Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Sosei Group Corporation, the world leader in GPCR-focused structure-based drug design (SBDD) and development, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares.

  9. A-Alpha Bio Partners With Kymera Therapeutics To Discover Novel Interactions For Molecular Glue Discovery 12/16/2021

    Alpha Bio, a biotechnology company that works with pharmaceutical industry partners to enable and accelerate drug discovery with massively multiplexed measurements of protein-protein interactions, and Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein degraders, today announced a partnership to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the rational and prospective design and development of molecular glues.

  10. Metrion Biosciences And Bioqube Ventures Collaborate On Venture Creation Project To Identify Novel Ion Channel Inhibitors For Autoimmune Diseases 12/16/2021

    Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and Bioqube Ventures (“Bioqube”), a specialist European life sciences investment firm, announced today that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.